Kevin Georgek is a litigation associate in the Intellectual Property Practice Group. His practice focuses on patent litigation arising under the Biologics Price Competition and Innovation Act and the Hatch-Waxman Act. Mr. Georgek also represents global pharmaceutical companies in complex antitrust litigation. During law school, Mr. Georgek was the Executive Editor of the Seton Hall Law Review and served as a judicial intern to Chief Judge Gary Sharpe of the Northern District of New York. Before law school, Mr. Georgek was an operations analyst at Regeneron Pharmaceuticals.
Before law school, Kevin Georgek worked as an operations analyst in the Industrial Operations and Product Supply group at Regeneron Pharmaceuticals. While at Regeneron, Mr. Georgek created long-range financial and operational forecasts and worked with the biologics manufacturing team to optimize the manufacturing process for Regeneron's EYLEA drug product.
